Cirrhosis

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver.

What is Cirrhosis?

Cirrhosis is a severe form of liver disease wherein normal liver tissue is replaced by scar tissue (fibrous tissue).

Managing and Treating Cirrhosis

What Causes Cirrhosis?

Liver Disease Symptoms

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Gut bacterial molecule discovered to drive serious bile duct disease

Researchers at the University of Oslo and Oslo University Hospital have, together with international collaborators, discovered that a small molecule made exclusively by gut bacteria can actively drive disease in the bile ducts and worsen primary sclerosing cholangitis (PSC), a serious liver and bile duct disease.

4 Sep 2026

Alcohol-related liver cancer deaths were falling. Then the trend reversed during the COVID-19 pandemic

A global analysis of GBD 2023 data found that alcohol-attributable liver cancer mortality increased modestly from 1990 to 2023, while mortality from alcohol-attributable cirrhosis, alcoholic cardiomyopathy, and alcohol use disorders declined. Liver cancer mortality shifted from a pre-pandemic decline to an increase during 2020–2023, particularly among women, although the researchers cautioned that the ecological analysis cannot establish that pandemic-related changes caused the reversal.

1 Sep 2026

Ketogenic diet excels at reversing prediabetes and fatty liver

There is no shortage of popular diets to try, and they can generally produce weight loss if followed to the letter. But are all diet plans created equal in terms of reducing the cardiometabolic risks that come with obesity, such as Type 2 diabetes and liver disease?

27 Aug 2026

Phytoene in tomatoes may help protect against fatty liver disease

New study suggests a lesser-known compound in tomatoes may help protect against fatty liver disease, which affects more than 1 in 3 American adults.

26 Aug 2026

Digital program reduces anxiety and depression in adults with chronic medical conditions

A digital program combining guided movement, breathing and meditation exercises, and coping-skills training reduced anxiety and depression symptoms in adults with chronic medical conditions, according to a new study published August 20th in the open access journal PLOS Medicine by Puneeta Tandon of the University of Alberta, Canada, and colleagues.

20 Aug 2026

Natural hormone activates brain-to-liver signaling pathway to suppress liver inflammation

Researchers at McMaster University have discovered that a naturally occurring hormone best known for suppressing appetite and promoting weight loss also helps protect the liver from inflammation through a previously unknown signalling pathway, opening new possibilities for treating advanced fatty liver disease.

10 Aug 2026

Genetic analysis of 1 million people points to FNIP1 as a promising metabolic target

Mega-scale exome sequencing of 1,032,116 people identified 59 independent genes linked to the TG:HDL ratio, including 44 rare-coding associations not detected in the previous largest analysis. Ultra-rare FNIP1 loss-of-function variants were associated with favorable fat distribution, lower liver fat and glycemia, and around 60% lower odds of a composite cardiometabolic disease outcome.

7 Aug 2026

Daily tomatoes lowered a key marker of liver fat in MASLD trial

An exploratory randomized trial found that 200 g of raw tomatoes plus 50 g of tomato sauce daily for six weeks produced a greater reduction in CAP-defined hepatic steatosis than a tomato-free diet in adults with MASLD. The improvement occurred without major weight or metabolic changes, but larger and longer trials are needed to confirm its clinical significance.

2 Aug 2026

AI-powered blood test detects liver cancer across distinct populations

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence (AI)-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

31 Jul 2026

Review outlines effective approaches to reduce recurrent hepatic encephalopathy

Hepatic encephalopathy (HE) is a neurologic complication of advanced liver disease, causing impaired functioning, reduced quality of life (QOL), and increased hospitalisation and mortality.

31 Jul 2026

Novel interventional approach successfully treats rare hepatic myelopathy

Hepatic myelopathy (HM) is a rare neurological complication of decompensated chronic liver disease that profoundly impairs quality of life.

28 Jul 2026

Europe risks missing target to eliminate viral hepatitis by 2030

While Europe has made steady progress in preventing hepatitis B and C, with the prevalence of hepatitis B now at near-zero levels among children below five years old, an uneven implementation of key measures means that the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat, according to new data from the European Centre for Disease Prevention and Control (ECDC) on World Hepatitis Day.

28 Jul 2026

Emerging PPAR therapies offer new hope for primary biliary cholangitis

Primary biliary cholangitis is a rare autoimmune disease that affects the liver and can progress to cirrhosis. It occurs when the immune system attacks the small bile ducts within the liver. As a result, bile builds up, leading to inflammation and progressive liver damage. Although a first-line treatment exists, 40% of patients do not respond adequately to it or cannot tolerate it, so new treatment options need to be developed.

23 Jul 2026

Study tests chronotype’s liver link and finds no significant association

Researchers found no significant association between chronotype and FibroScan-derived liver fat or stiffness in 119 medication-naïve adults with overweight or obesity. The exploratory findings cannot exclude smaller effects, particularly for fibrosis, and require confirmation in larger longitudinal studies.

21 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

Experts urge Mexico to integrate liver disease into chronic care

Liver disease may affect close to half of adults in Mexico, yet the country tracks it far less closely than the diabetes and obesity to which it is linked, according to a new paper by Jeffrey Lazarus, professor at the CUNY Graduate School of Public Health and Health Policy Professor (CUNY SPH), and colleagues, and released to coincide with the International Congress on Obesity taking place in Mexico City this week.

14 Jul 2026

New drug candidate treats severe fatty liver disease by improving gut health

Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving gut health, according to a study published in The Journal of Clinical Investigation.

7 Jul 2026

Experts reframe steatotic liver disease as a dynamic continuum

The classification of steatotic liver disease (SLD) is undergoing a major conceptual transformation. In a recent article published in eGastroenterology, Dr. Chen, Dr. Horn, and Prof. Tacke from Charité - Universitätsmedizin Berlin argue that metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) should not be regarded as rigid diagnostic categories, but rather as interconnected and evolving disease trajectories.

30 Jun 2026

Unusual CD34+ dysplastic giant platelets complicate myelodysplastic syndrome diagnosis

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by ineffective hematopoiesis, with manifestations of cytopenias in one, two, or three lineages.

28 Jun 2026